Tilray Acquires HelloMD to Expand Medical Cannabis Digital Platform

Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) announced the acquisition of HelloMD Corporation, a digital healthcare and patient engagement platform focused on medical cannabis. The deal was disclosed in a company press release.

Tilray was the winning bidder in a formal sale process for HelloMD and will acquire its Canadian medical cannabis assets following expected court approval on June 29th, 2026. Financial terms of the transaction were not disclosed.

Acquisition Overview and Strategic Context

The acquisition comes during a challenging trading period for Tilray, with the stock recently priced at $4.61 per share after a six-month decline of nearly 50%. The company currently has a market capitalization of $549.89 million. HelloMD has supported hundreds of thousands of patients through its digital healthcare platform, which focuses on medical cannabis education, telehealth consultations, and patient engagement services.

HelloMD Corporation operates as a digital healthcare platform that connects patients with healthcare professionals to provide guidance on medical cannabis treatment. Its services include physician consultations, educational content, and ongoing patient support tools designed to improve access to medical cannabis care.

Integration Benefits and Tilray’s Positioning

The acquisition adds HelloMD’s telehealth services, educational resources, and digital healthcare infrastructure to Tilray’s existing medical cannabis operations. According to Tilray Canada President Blair MacNeil, the acquisition “establishes a fully vertically integrated medical cannabis framework for Tilray in Canada, while strengthening our broader global platform, expanding patient engagement, support for healthcare professionals, and access in regulated medical markets.”

This integration is intended to enhance Tilray’s presence in the medical cannabis sector by combining cultivation, distribution, and patient engagement capabilities under one structure. The company already supplies medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments across 20 countries on five continents.

Tilray also operates EU-GMP certified cultivation and manufacturing facilities, pharmaceutical distribution through CC Pharma, and medical cannabis clinics across North America, Europe, Australia, and other international markets. The addition of HelloMD is expected to strengthen its digital healthcare capabilities within this global framework.

HelloMD CEO Larry Lisser stated that the company’s mission has been “to make medical cannabis more accessible through innovative technology, accessible education, and trusted healthcare experiences.” This aligns with Tilray’s stated goal of increasing awareness of medical cannabis alternatives among individuals seeking natural health solutions, subject to regulatory compliance.

Tilray noted that it plans to leverage HelloMD’s digital platform to expand patient engagement and improve access to medical cannabis information and services. The integration is expected to enhance communication between patients and healthcare professionals and improve the overall accessibility of medical cannabis care.

Cannabis company Tilray currently reports revenues of $858.27 million over the past twelve months. The company has indicated expectations for sales growth and potential profitability, supported by its international operations and expanding product and service portfolio.

Overall, the acquisition of HelloMD represents a strategic expansion of Tilray’s medical cannabis ecosystem, combining digital healthcare tools with its existing cultivation and distribution infrastructure to strengthen its position in regulated medical markets.

__

(Featured image by sergeitokmakov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in investing.com. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.